Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease. - Wikidata - awgldk - TriplyDB

Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease.

Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease.

http://www.wikidata.org/entity/Q34568763

about

Inflammation and nutrition in children with chronic kidney disease RNA-seq and metabolomic analyses of Akt1-mediated muscle growth reveals regulation of regenerative pathways and changes in the muscle secretome.Arteriovenous fistula creation may slow estimated glomerular filtration rate trajectory Extracellular vesicle microRNAs mediate skeletal muscle myogenesis and disease Response: "Commentary: A Hypothesis for Examining Skeletal Muscle Biopsy-Derived Sarcolemmal nNOSµ as Surrogate for Enteric nNOSα Function". nNOS(skeletal muscle) may be Evidentiary for Enteric NO-Transmission Despite nNOSµ/α Differences.Negative energy balance induced by paradoxical sleep deprivation causes multicompartmental changes in adipose tissue and skeletal muscle.Can muscle-kidney crosstalk slow progression of CKD?

P2860

Q26751530-06473341-CCFF-40F9-B286-ABD56A72335E Q36283290-65DDAE4B-A41B-45F5-9958-8FB23F24083C Q36801578-B18B810D-298F-408E-8C3F-0E9BD79B3F9B Q37204128-C82DFE05-97A1-4D2E-9211-B04AB48F37D4 Q38581476-D2AF47AB-89EB-44FA-BB15-105C40B11DCA Q41142405-D5928748-2E9E-47DD-BBDC-71ABE2CA3493 Q43030396-A36E39FB-AC1A-4EF6-A6CE-5FEFA7C42D85

P2860

Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease.

http://www.wikidata.org/entity/Q34568763

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@ast

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@en

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@nl

type

label

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@ast

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@en

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@nl

prefLabel

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@ast

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@en

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@nl

P1433

Q34568763-8C537FD6-388D-4B44-BC77-80B52711DBDF

P1476

Q34568763-E276B787-DA29-469E-9913-85ACA8FF5350

P2093

Q34568763-05FE8E2B-08CA-4F38-A3F9-74A2F70BD85C

Q34568763-30EFAB27-0ECA-49FB-BD89-68903B9090A3

Q34568763-4A17BAB8-6B88-4F2D-B1DF-44896BD8E7FD

Q34568763-79AC0E3A-8E70-4868-950A-E14DD631EAE1

Q34568763-7D953BAB-45F2-4ABE-A005-0567E2222E84

Q34568763-8814E031-D183-4667-B203-CDDC2C48E3FE

Q34568763-9C0BCDDB-6003-43DC-AC8D-52B7FB1A9030

P2860

Q34568763-02B893FE-208F-4CE2-8E92-A9F92F92A6B6

Q34568763-08528DB7-036E-4DA4-9E0C-64D5FB9CAA9A

Q34568763-0B24CFCC-29F9-4FF4-B427-F91E6FEBC0CB

Q34568763-14AE426F-1038-4978-A48B-8443225845E7

Q34568763-22087BC0-8A45-4876-9831-96A37E0DF7F9

Q34568763-2CAF19B1-E762-42A1-A32F-CA28908EAF6F

Q34568763-37263AFA-F62D-457C-998B-801E7AEA81AD

Q34568763-3A996A62-3475-44B7-A2F7-EBB6B4D184C8

Q34568763-3BB551F4-58DE-4F7A-9FC9-7953C389396E

Q34568763-3DCBE23C-26AE-4F91-840B-90C558E3EFB2

P304

Q34568763-F1724EA5-7743-4855-BCDC-06A722F07BDE

P31

Q34568763-46F429E5-813F-4F94-BF2F-537B614F2F62

P356

Q34568763-2C942549-0D4E-44EC-9E42-709A8626836F

P433

Q34568763-1D5F929B-E0BA-4583-B096-1D0D4355BBE0

P478

Q34568763-8CF1D4FA-D659-4C73-ACFF-89F37308BC1E

P577

Q34568763-789B98B3-3699-4699-A722-873C03CB3342

P698

Q34568763-B7D873A4-03D7-420C-9F07-86C3F6CD75E4

P932

Q34568763-A5A1737B-3328-4651-9AA4-541E39CCE6C9

P356

P1433

Journal of the American Society of Nephrology

P1476

Akt1-mediated fast/glycolytic ...... n experimental kidney disease.

@en

P2093

Hisao Ogawa

http://www.w3.org/2001/XMLSchema#string

Kenneth Walsh

http://www.w3.org/2001/XMLSchema#string

Satoshi Araki

http://www.w3.org/2001/XMLSchema#string

Shinsuke Hanatani

http://www.w3.org/2001/XMLSchema#string

Taku Rokutanda

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Izumiya

http://www.w3.org/2001/XMLSchema#string

Yuichi Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease

Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation

Cellular survival: a play in three Akts

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy

Resistance training increases muscle mitochondrial biogenesis in patients with chronic kidney disease

TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury.

Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta.

Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice.

Exercise attenuates renal dysfunction with preservation of myocardial function in chronic kidney disease

P304

2800-2811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013091025

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25012168

http://www.w3.org/2001/XMLSchema#string

P932

4243347

http://www.w3.org/2001/XMLSchema#string